Continuous Glucose Monitoring for Low Blood Sugar

This trial aims to understand the relationship between gut bacteria and blood sugar levels after meals, particularly for individuals experiencing low blood sugar symptoms post-eating. Participants will use a Dexcom continuous glucose monitor to track blood sugar levels and an activity tracker for two weeks. Researchers will study gut bacteria using a stool sample. Ideal participants are those who have undergone stomach surgery and experience low blood sugar symptoms after meals.

As an unphased trial, this study offers participants the chance to contribute to groundbreaking research that could improve the management of post-meal blood sugar issues.

The trial requires that you stop taking certain medications, such as diabetes medications (except acarbose), β-blockers, octreotide, diazoxide, and corticosteroids. If you are on any of these, you would need to stop them to participate.

Research has shown that the Dexcom continuous glucose monitor (CGM) is generally safe. Studies have found no serious health problems linked to the Dexcom G7 CGM, indicating that users did not experience major health issues from it.

Researchers are excited about this trial because it explores the use of Dexcom continuous glucose monitors (CGM) to potentially improve our understanding of low blood sugar management. Unlike traditional methods that rely on periodic blood tests, the CGM provides continuous data on glucose levels without the participant being aware of the readings. This could reveal more precise patterns in blood sugar fluctuations, especially after meals. Additionally, the integration of microbiome analysis through stool samples could offer insights into how gut bacteria might influence blood sugar levels, paving the way for more personalized treatment strategies.

Studies have shown that using a Dexcom continuous glucose monitor (CGM) can greatly reduce instances of low blood sugar, also known as hypoglycemia. For example, one study found that people using Dexcom CGMs experienced 72% fewer episodes of low blood sugar. Another study demonstrated that using a CGM led to an average 1% drop in A1C levels, which measure long-term blood sugar. The evidence strongly suggests that CGMs help control blood sugar and lower the risk of severe low blood sugar. In this trial, participants will wear a Dexcom CGM and activity monitor to evaluate relationships between patterns of postprandial glycemia, food intake, and microbiome composition. These findings are promising for those seeking to manage hypoglycemia more effectively.⁶⁷⁸⁹¹⁰